State Street SPDR S&P Biotech ETF (NY:XBI)

150.23 UNCHANGED

Delayed Quote Updated: 8:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

How Are Biotech ETFs Reacting To These Q3 Earnings Releases? ↗

November 06, 2021

There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see...

Via Talk Markets

Wednesdays With Wedbush On PreMarket Prep Plus ↗

November 03, 2021

On the PreMarket Prep Plus "Wednesday’s With Wedbush" segment, Sahak Manuelian, managing director and head of equi...

Via Benzinga

15 Charts All Traders Should Look At Every Morning ↗

September 30, 2021

One of the hardest things to do as a day trader is gathering all the necessary information to execute profitable trades. Below are the to...

Via Benzinga

Look For The Q4 Biotech Bounce In Mid-Small Caps ↗

September 17, 2021

Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best...

Via Talk Markets

Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗

August 11, 2021

SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares...

Via Benzinga

Topics Stocks

Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗

August 09, 2021

SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares...

Via Benzinga

Topics Stocks

Unusual Options Activity Insight: SPDR Series Trust SPDR S&P Biotech ETF ↗

August 06, 2021

On Friday, shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:

Via Benzinga

Topics Stocks

Understanding SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗

August 03, 2021

Shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI

Via Benzinga

Topics Stocks

Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market ↗

September 09, 2021

Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day.

Via Talk Markets

Healthcare Stocks Hit New Highs but Small Caps Lag ↗

August 23, 2021

Many smaller cap biotech stocks trade on news and milestones and have no earnings so require more expertise in the field.

Via Talk Markets

ETF Reflections: US Stocks ↗

August 21, 2021

I'm a bear. So the longer they prop this dreck up, the greater the fall. Suits me!

Via Talk Markets

Biotech ETFs To Benefit From Latest Booster Update ↗

August 21, 2021

Vaccine makers like Moderna and Pfizer have reasons to cheer the update with regard to the application of boosters. The U.S. government announced plans to make COVID-19 vaccine boosters available from...

Via Talk Markets

Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗

August 16, 2021

On Monday, shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) saw unusual options activity. After the option alert, the stock price moved down to $122.44. Sentiment...

Via Benzinga

Topics Stocks

Unusual Options Activity Insight: SPDR Series Trust SPDR S&P Biotech ETF ↗

July 30, 2021

SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares...

Via Benzinga

Topics Stocks

Large Cap Biopharma Stocks provide Growth and Value ↗

August 16, 2021

The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD.

Via Talk Markets

Topics Stocks

ETF Investing Areas to Consider for August ↗

August 09, 2021

There is no doubt that the second-quarter 2021 earnings season is going strong.

Via Talk Markets

Carter Worth And Mike Khouw's XBI Trade ↗

August 08, 2021

On CNBC's "Options Action," Carter Worth of Cornerstone Macro said SPDR S&P Biotech ETF (NYSE: XBI) has a bounce potential, having sold off to support. XBI is an...

Via Benzinga

Topics Stocks

Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗

July 27, 2021

Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity Shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE: XBI) saw some unusual options activity...

Via Benzinga

Topics Stocks

Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗

July 15, 2021

On Thursday, shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) saw unusual options activity. After the option alert, the stock price moved up to $126.24. Sentiment...

Via Benzinga

Topics Stocks

Understanding SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗

July 12, 2021

Shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved down to $132...

Via Benzinga

Topics Stocks

Mid-Cap Biotech Picks: Seasonal Rally Underway ↗

July 03, 2021

Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable.

Via Talk Markets

IBB Vs. XBI: Which Biotech ETF Has A Better Chart? ↗

June 30, 2021

The SPDR S&P Biotech ETF XBI is trading below an important resistance level, but the iShares Nasdaq Biotechnology ETF IBB has broken out.

Via Talk Markets

Topics Stocks

IBB Vs. XBI: Which Biotech ETF Has A Better Chart? ↗

June 30, 2021

The SPDR S&P Biotech ETF (NYSE: XBI) is trading below an important resistance level, but the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) has broken out. Resistance is a...

Via Benzinga

Topics Stocks

Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated ↗

June 29, 2021

Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust ...

Via Benzinga

Healthcare Portfolio Playbook: Time To Rebalance With MedTech ↗

June 18, 2021

As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap...

Via Talk Markets

Should You Buy Biotech ETFs Now? ↗

June 16, 2021

Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and...

Via Talk Markets

Tuesday Talk: Action! ↗

June 15, 2021

U.S. stock markets started the week in continued action mode. The S&P 500 closed at 4,255, up nearly 8 points, the Dow closed at 34,394, down 85 points and the Nasdaq Composite closed at 14,174, up...

Via Talk Markets

Topics Stocks

Biotechs Ready To Roar ↗

June 13, 2021

The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector...

Via Talk Markets

3 Biotech ETFs That Could Double Your Money by 2025 With Zero Effort ↗

June 13, 2021

In a sector where picking individual stocks is a high-risk, high-reward strategy, the diversification of exchange-traded funds can be highly appealing.

Via The Motley Fool

Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗

June 11, 2021

SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares experienced unusual options activity on Friday. The stock price moved up to $136.19 following the option alert....

Via Benzinga

Topics Stocks

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.